+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Macular Edema Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309787

Global Diabetic Macular Edema Treatment Market to Reach $4.9 Billion by 2030

The global market for Diabetic Macular Edema Treatment estimated at US$4.1 Billion in the year 2022, is projected to reach a revised size of US$4.9 Billion by 2030, growing at a CAGR of 2.1% over the analysis period 2022-2030. Anti-VEGF, one of the segments analyzed in the report, is projected to record 2.4% CAGR and reach US$2.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroid segment is readjusted to a revised 2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 1.8% CAGR

The Diabetic Macular Edema Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$855.8 Million by the year 2030 trailing a CAGR of 1.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 1.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Select Competitors (Total 38 Featured) -

  • Acucela Inc.
  • Aerie Pharmaceuticals, Inc.
  • Aerpio Pharmaceuticals
  • Antisense Therapeutics Limited
  • Araim Pharmaceuticals, Inc.
  • BCN Peptides S.A.
  • Biomar Microbial Technologies
  • Charlesson LLC
  • Coherus BioSciences

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Diabetic Macular Edema Treatment

What is the estimated value of the Global Market for Diabetic Macular Edema Treatment?

The Global Market for Diabetic Macular Edema Treatment was estimated to be valued at $4.1 Billion in 2022.

What is the growth rate of the Global Market for Diabetic Macular Edema Treatment?

The growth rate of the Global Market for Diabetic Macular Edema Treatment is 2.3%, with an estimated value of $4.9 Billion by 2030.

What is the forecasted size of the Global Market for Diabetic Macular Edema Treatment?

The Global Market for Diabetic Macular Edema Treatment is estimated to be worth $4.9 Billion by 2030.

Who are the key companies in the Global Market for Diabetic Macular Edema Treatment?

Key companies in the Global Market for Diabetic Macular Edema Treatment include Acucela Inc., Aerie Pharmaceuticals, Inc., Aerpio Pharmaceuticals, Antisense Therapeutics Limited, Araim Pharmaceuticals, Inc., BCN Peptides S.A., Biomar Microbial Technologies, Charlesson LLC and Coherus BioSciences.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Diabetic Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Corticosteroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Diabetic Macular Edema Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 15: USA Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: USA 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
CANADA
  • Table 17: Canada Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: Canada Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: Canada 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
JAPAN
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 20: Japan Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: Japan Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: Japan 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
CHINA
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 23: China Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: China Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: China 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
EUROPE
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Europe 16-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 29: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: Europe 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
FRANCE
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 32: France Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: France Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: France 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
GERMANY
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 35: Germany Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Germany Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Germany 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
ITALY
  • Table 38: Italy Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Italy Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Italy 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 41: UK Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: UK Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: UK 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 44: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Rest of Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Rest of Europe 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 47: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Asia-Pacific Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Asia-Pacific 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
REST OF WORLD
  • Table 50: Rest of World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Rest of World Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Rest of World 16-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Acucela Inc.
  • Aerie Pharmaceuticals, Inc.
  • Aerpio Pharmaceuticals
  • Antisense Therapeutics Limited
  • Araim Pharmaceuticals, Inc.
  • BCN Peptides S.A.
  • Biomar Microbial Technologies
  • Charlesson LLC
  • Coherus BioSciences